Caribou Biosciences, Inc. (CRBU) Stock Price & Analysis

Caribou Biosciences, Inc. (CRBU) fell 0.34% to USD 1.57 as of September 8, 2026 at 19:20 UTC, according to Nexqual real-time market data.

CRBU last closed at USD 1.57; the session ranged USD 1.54–1.58 on volume of 510,106 shares. Market capitalization is —, with a 52-week range of USD 1.38–3.54 (NMS). Source: Nexqual, September 8, 2026 at 19:20 UTC.

Key Statistics (as of September 8, 2026 at 19:20 UTC)

Technical Analysis (CRBU)

Nexqual's technical model rates CRBU "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of September 8, 2026 at 19:20 UTC.

From Caribou Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)

Key Strengths & Strategy (as disclosed to the SEC)

• Pfizer Investment On June 29, 2023, we entered into a Securities Purchase Agreement ("Securities Purchase Agreement") with Pfizer Inc. ("Pfizer"), pursuant to which we, in a private placement transaction, sold to Pfizer 4,690,431 shares of our common stock, par value $0.0001 per share, at a purchase price of $5.33 per share, for aggregate gross proceeds of approximately $25.0 million ("Pfizer Investment").
• Our CRISPR chRDNA genome-editing technology is designed to address these limitations and enables us to apply armoring strategies to enhance allogeneic CAR-T cell therapy activity against diseases.
• CD19 and BCMA antigens are the targets of several commercially available autologous CAR-T cell therapies, which reduces target risk as we evaluate the safety and efficacy of our allogeneic CAR-T cell therapies in clinical trials. • Pursuing select applications of our technology and indications on our own and through new strategic collaborations.
• We believe that our technology has broad potential to generate cell and gene therapies in oncology, autoimmune diseases, and additional therapeutic areas.

Partnerships

• ProMab Biotechnologies, Inc. ("ProMab") On January 31, 2020, we entered into a Sale and Assignment Agreement with ProMab (as amended, "ProMab Agreement") under which we purchased a humanized scFv targeting BCMA and a patent family related thereto for an upfront cash payment of $0.4 million and the potential payments of future royalties to ProMab.
• On June 16, 2021, we entered into a leaseback agreement with Intellia ("Leaseback Agreement"), which resolved the arbitration proceeding.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 19:20 UTC. This page is informational and not investment advice.